Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + disitamab vedotin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pembrolizumab + disitamab vedotin is an investigational combination therapy being studied primarily for the treatment of HER2-expressing, locally advanced or metastatic urothelial carcinoma. Pembrolizumab is a monoclonal antibody that targets programmed cell death protein 1 (PD‑1), acting as an immune checkpoint inhibitor to enhance antitumor immune responses. Disitamab vedotin is an antibody-drug conjugate consisting of a fully humanized HER2-directed monoclonal antibody (disitamab) linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Disitamab vedotin exerts its effects through direct cytotoxicity, bystander effect, and immunogenic cell death in HER2-expressing tumor cells. The rationale for combining these agents is based on evidence that MMAE-based ADCs can induce immunogenic cell death and may synergize with PD‑1 inhibition to improve clinical outcomes[1][2][8].
- Other names
- pembrolizumab plus disitamab vedotinDV + pembro
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + disitamab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + disitamab vedotin.